Transcripta Bio Announces $24 Million Funding

Transcripta Bio said it has raised $24 million since its Series A to advance its AI-driven drug discovery pipeline.

The funds will support IND-enabling studies and clinical preparation for programs in autism spectrum disorder and facioscapulohumeral muscular dystrophy.

Mayo Clinic and Omnimed joined existing backers including JAZZ Venture Partners and BlueYard Capital.

The financing moves the company closer to human trials across several serious neurological and neuromuscular diseases.